Skip to main content
Top
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Research article

Oncologic results of Nephron sparing endoscopic approach for upper tract low grade transitional cell carcinoma in comparison to nephroureterectomy – a case control study

Authors: Azik Hoffman, Ofer Yossepowitch, Yaron Erlich, Ronen Holland, David Lifshitz

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

There is paucity of data as to the results of the endoscopic approach in comparison to the golden standard of nephro-ureterectomy in elective, low grade TCC, patients. Our purpose is to report our results of a nephron sparing approach compared to nephro-ureterectomy in those patients.

Methods

From a retrospective data base we identified 25 patients and 23 patients who underwent a nephron sparing ureterosocpic resection and nephro-reterectomy for low grade UT-TCC, respectively. The endoscopic technique included endoscopic tumor biopsy followed by primary resection and/or fulguration. The nephron sparing group was followed by bi-annual ureteroscopy and upper tract imaging, timely cystoscopy and urine cytology collection. Data for overall and disease related mortality, bladder and ureteral TCC recurrence and renal function are reported in both groups.

Results

Median follow - up time was 26 months. 11 (44%) patients developed bladder recurrence at a median period of 9 months after initial ureteroscopy, compared to 9 (39%) in the NUx group (P < 0.05). Recurrent ureteral low grade TCC was observed in 9 patients (median: 9 months). All were treated endoscopicaly successfully. Renal function remained stable in the nephron sparing group. No disease related mortality was recorded in the nephron-sparing group while one patient died of his disease following NUx.

Conclusions

Disease related mortality following a nephron sparing endoscopic approach or nephroureterectomy for low grade upper tract TCC is excellent. However, the nephron sparing approach is associated with a relatively high rate of ureteral and bladder recurrence. Therefore, a stringent follow-up protocol is required.
Appendix
Available only for authorised users
Literature
1.
go back to reference Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW, Bagley DH: Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol. 2005, 23: 114-122. 10.1016/j.urolonc.2004.10.010.CrossRefPubMed Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW, Bagley DH: Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol. 2005, 23: 114-122. 10.1016/j.urolonc.2004.10.010.CrossRefPubMed
2.
go back to reference Murphy DP, Gill IS, Streem SB: Evolving management of upper-tract transitional-cell carcinoma at a tertiary-care center. J Endourol. 2002, 16: 483-487. 10.1089/089277902760367449.CrossRefPubMed Murphy DP, Gill IS, Streem SB: Evolving management of upper-tract transitional-cell carcinoma at a tertiary-care center. J Endourol. 2002, 16: 483-487. 10.1089/089277902760367449.CrossRefPubMed
3.
go back to reference Roupreˆt M, Babjuk M, Compe´rat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bo¨hle A, Van Rhijn BWG, Kaasinen E, Palou J, Shariat SF: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Urol. 2001, 59: 584-594.CrossRef Roupreˆt M, Babjuk M, Compe´rat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bo¨hle A, Van Rhijn BWG, Kaasinen E, Palou J, Shariat SF: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Urol. 2001, 59: 584-594.CrossRef
4.
go back to reference Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, Alberta Kidney Disease Network: Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010, 303: 423-429. 10.1001/jama.2010.39.CrossRefPubMed Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, Alberta Kidney Disease Network: Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010, 303: 423-429. 10.1001/jama.2010.39.CrossRefPubMed
6.
go back to reference Rai BP, Shelley M, Coles B, Biyani CS, El-Mokadem I, Nabi G: Surgical management for upper urinary tract transitional cell carcinoma. Cochrane Database Syst Rev. 2011, [Art. No: CD007349. doi:10.1002/14651858.CD007349.pub2], Issue 4CrossRef Rai BP, Shelley M, Coles B, Biyani CS, El-Mokadem I, Nabi G: Surgical management for upper urinary tract transitional cell carcinoma. Cochrane Database Syst Rev. 2011, [Art. No: CD007349. doi:10.1002/14651858.CD007349.pub2], Issue 4CrossRef
7.
go back to reference Grasso M, Fishman AI, Cohen J, Alexander B: Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012, 110: 1618-1626. 10.1111/j.1464-410X.2012.11066.x.CrossRefPubMed Grasso M, Fishman AI, Cohen J, Alexander B: Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012, 110: 1618-1626. 10.1111/j.1464-410X.2012.11066.x.CrossRefPubMed
8.
go back to reference Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS: Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol. 2010, 183: 2148-2153. 10.1016/j.juro.2010.02.005.CrossRefPubMed Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS: Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol. 2010, 183: 2148-2153. 10.1016/j.juro.2010.02.005.CrossRefPubMed
9.
go back to reference Sowter SJ, Ilie CP, Efthimiou I, Tolley DA: Endourologic management of patients with upper-tract transitional-cell carcinoma: long-term follow-up in a single center. J Endourol. 2007, 21: 1005-1009. 10.1089/end.2006.9922.CrossRefPubMed Sowter SJ, Ilie CP, Efthimiou I, Tolley DA: Endourologic management of patients with upper-tract transitional-cell carcinoma: long-term follow-up in a single center. J Endourol. 2007, 21: 1005-1009. 10.1089/end.2006.9922.CrossRefPubMed
10.
go back to reference Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML: Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008, 71: 713-717. 10.1016/j.urology.2007.11.018.CrossRefPubMed Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML: Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008, 71: 713-717. 10.1016/j.urology.2007.11.018.CrossRefPubMed
11.
go back to reference Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA: Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012, 110: 614-628. 10.1111/j.1464-410X.2012.11068.x.CrossRefPubMed Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA: Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012, 110: 614-628. 10.1111/j.1464-410X.2012.11068.x.CrossRefPubMed
Metadata
Title
Oncologic results of Nephron sparing endoscopic approach for upper tract low grade transitional cell carcinoma in comparison to nephroureterectomy – a case control study
Authors
Azik Hoffman
Ofer Yossepowitch
Yaron Erlich
Ronen Holland
David Lifshitz
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-97

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue